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Pseudozyma aphidis is an environmental Basidiomycete yeast, and has been involved in the ten past years
in rare cases of invasive infection. Pseudozyma species are naturally resistant to caspofungin and often
present decreased susceptibility or resistance to ﬂuconazole. This fungus may be difﬁcult to recognize
and misidentiﬁcations are reported with conventional phenotypical methods. We report a case of P.
aphidis invasive infection in an adult with a metastatic ampulloma who had gone through digestive
surgery.
& 2015 The Authors. International Society for Human and Animal Mycology Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rare yeasts are considered as having a low pathogenicity, but
are still responsible for 1.1–5.1% of fungemias. This is most likely
due to the increasing number of immunocompromised patients
and also to the improvement of mycological diagnosis, especially
molecular biology techniques [1,2].
Indeed, in the past decades, we have seen the emergence of
yeasts that had never been described as invasive pathogens before,
such as Saccharomyces spp., Rhodotorula spp. or Trichosporon spp.
A recent study has looked more closely into rare yeast infections in
patients with cancer, and found that the incidence of these in-
fections increased from 1.8 to 2.35 cases per 100,000 patient-days
between 1998 and 2010 [3]. In this study, 95% of the patients had a
central venous catheter, and the presence of a catheter was con-
sidered responsible for 45% of those infections.
The anamorphic basidiomycetous genus Pseudozyma belongs to
the Ustilaginomycetes class and includes 16 species. Pseudozyma
species are common environmental yeasts generally isolated from
plant leaves, ﬂowers or soil. Some species have recently (since
2003) been involved in invasive infections, such as fungemia [4–8],
pulmonary infection [9], brain abscess [10], and mycetoma [11].for Human and Animal Mycology
d/4.0/).
e et de Pathologie Tropicale,
iversité de Strasbourg, 3 rue
u).We here report what we believe, to our best knowledge, to be
the ﬁrst case of a Pseudozyma aphidis invasive infection in an adult
with a metastatic ampulloma, who underwent heavy digestive
surgery. The evolution was favorable after two weeks of in-
travenous liposomal amphotericin B.2. Case report
A 68 year old woman was hospitalized in the University Hos-
pital of Strasbourg, France. She was admitted to a digestive surgery
unit for the management of a metastatic adenocarcinoma of the
ampulla of Vater. She had not yet undergone chemotherapy, and
went through a pancreaticoduodenectomy and lymphadenectomy
on April 23rd 2014 (day 0), during which a sample of bile was
taken and sent to the Bacteriology Laboratory. She received no
antifungal chemoprophylaxis. Subsequently to this surgery, a
central venous catheter and drains were placed. Because the bile
culture was positive for Enterococcus faecalis and Klebsiella pneu-
moniae on day þ1, a bi-antibiotherapy was started with mer-
openem and vancomycine for 19 days.
On day þ22, she started to shiver with fever of 38.5 °C. Two
blood cultures were then drawn the same day on a peripheral vein
onto BACTEC™ Mycosis-IC/F and BACTEC™ Plus Aerobic/F Med-
ium, and remained negative after seven days of incubation in a
BACTEC™ FX (Becton Dickinson). Two others were drawn on day
þ23 on the central venous catheter onto BACTEC™ Mycosis-IC/FPublished by Elsevier B.V. This is an open access article under the CC BY-NC-ND
Fig. 2. P. aphidis colonies on chromID Candida agar after 8 days of incubation at
27 °C. The reverse of some colonies is blue.
Fig. 3. P. aphidis colonies on a Sabouraud Chloramphenicol agar after 4 days of
incubation at 27 °C.
Fig. 4. Potato Carrot Bile Agar slide culture after 4 days of incubation at 27 °C.
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day þ26 and on day þ27, which is after 84 h (Mycosis) and 100 h
(Aerobic/F Medium) of incubation at 35 °C. Microscopic examina-
tion of the blood cultures revealed unusual fungal elements.
A treatment with intravenous ﬂuconazole 800 mg/day had
been initiated on the evening of day þ26, and was then switched
to liposomal amphotericin B 3 mg/kg/day on the next day in order
to have a larger antifungal spectrum.
The central venous catheter was withdrawn on day þ23 and
sent to the Bacteriology Laboratory of the hospital, where it re-
mained negative after 48 h of incubation. Cultures were then
eliminated according to bacteriological procedures. The control
blood cultures, taken on a peripheral vein after the catheter re-
moval, remained negative. No other specimen was addressed to
the Mycology Laboratory.
The patient then developed a septic shock on day þ27. Blood
cultures drawn that same day on a peripheral vein, on an arterial
catheter and on a central venous catheter were positive to Candida
albicans and Candida glabrata. The patient was transferred to an
intensive care unit. The evolution was favorable, and she was ad-
mitted back in the digestive surgery unit, where the liposomal
amphotericin B was continued on for a total of two weeks.
The ﬁrst positive blood cultures showed unusual fungal ele-
ments at direct examination, with short hyphae and fusiform cells
with polar buddings (Fig. 1).
The blood was then subcultured on chromID™ Candida agar
(Biomérieux, France) and on Sabouraud-Chloramphenicol-Agar at
27 °C and 35 °C. The isolate grew in about 24 h on both media. A
better growth was observed at 27 °C. The colonies were ﬁrst blue
on the chromogenic medium, and then they produced a yellow-
beige pigment, which was also the color observed on the Sa-
bouraud-Chloramphenicol-Agar (Figs. 2 and 3). After several days
of culture, the colonies looked tan, dry and wrinkled.
Microscopic examination of the colonies showed morphologi-
cal aspects similar to those observed on positive blood cultures.
An analysis of the isolate on a Microﬁlex™ MALDI-TOF mass
spectrometer (Bruker, Germany) using the Biotyper Software
(Bruker), was performed but was inconclusive as P. aphidis was
suggested, but with an insufﬁcient score (between 1.5 and 1.6).
The APID 32C strip (bioMérieux, France) was also inconclusive.
The yeast was urease positive and nitrate positive.
Morphological study on Potato-Carrot-Bile medium (Bio-Rad,
USA) incubated in a semi anaerobiosis at 27 °C produced more
regular elements compatible with the genus Pseudozyma (Fig. 4).
Final identiﬁcation was obtained by sequencing (GATC Biotech
AG, Germany) of the ITS region followed by GenBank and CBS
analysis, giving a 99% and a 99.7% match to P. aphidis (sequencesFig. 1. Direct examination of the ﬁrst positive blood culture.JQ425372.1 and DQ778919.1), respectively.
The susceptibility of the isolate was tested by the Etest method
(BioMérieux, France) on a RPMI medium, and it showed MIC va-
lues of 16 mg/mL for ﬂuconazole, 0.19 mg/mL for itraconazole,
0.032 mg/mL for voriconazole, 0.094 mg/mL for posaconazole,
0.19 mg/mL for amphotericin B, 432 mg/mL for caspofungin and
432 mg/mL for ﬂucytosine.3. Discussion
Only a few Pseudozyma species have yet been reported as re-
sponsible for human invasive infection, in a limited number of
cases. This is the fourth description of an invasive infection due to
P. aphidis, and the ﬁrst adult case. There is no report of docu-
mented colonization by this species in human patients. However
Gil et al. have previously described respiratory colonization by
Pseudozyma spp. without species identiﬁcation [12]. Thirty strains
were isolated from respiratory samples between 1997 and 2001. In
all cases, the fungus was not isolated repeatedly and was con-
sidered as a colonizer; no antifungal treatment was considered
Table 1
MICs of P. aphidis strains isolated from patients with invasive infection.
MIC (lg/mL) P. aphidis isolates
Our isolate Neonatal
fungemia [4]
Fungemia in a
short gut syn-
drom [5]
Pulmonary in-
fection in a
Burkitt [6]
Fluconazole 16 8 4 4
Itraconazole 0.19 0.03 0.125 0.25
Voriconazole 0.032 0.03 0.03
Posaconazole 0.094 0.03
Isavuconazole 0.25
Amphotericin B 0.19 0.03 0.25 0.25
Flucytosine 432 464
Caspofungin 432 48
Micafungin 48 44
Anidulafungin 44
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P. aphidis infections might be underdiagnosed, due to the fact
that, at the moment, only sequencing allows an accurate identiﬁ-
cation of this yeast. Misidentiﬁcations as Cryptococcus or Trichos-
poron species have been described with the VITEK 2 (bioMérieux),
The ID32Cs (bioMérieux), the RapID Yeast Pluss (Remel) systems
[8,12]. For our isolate, mass spectrometry analysis suggested P.
aphidis but with a low score, which is most likely due to an in-
sufﬁcient number of spectra in the databank, and the API 32C
identiﬁcation algorithm does not include this species in its
databank.
The risk factors described in all reports of invasive Pseudozyma
infection were immunosuppression, neoplastic diseases, impaired
mucosal defenses and foreign material, such as a central venous
catheter. In our case, the patient had several risk factors: a meta-
static adenocarcinoma of the ampulla of Vater, abdominal surgery
and a central venous catheter. Her blood count was normal and
did not reveal any cytopenia.
We could not document the portal of entry of the infection;
however the central venous catheter remains the most probable
hypothesis, as the control blood cultures after its removal were
negative.
The choice of the ﬁrst line antifungal therapy is important in
case of non-Candida yeasts, as many other genera are resistant to
caspofungin and/or azoles.
Only a few data are available for P. aphidis in the literature.
Table 1 resumes the characteristics of the strains isolated from
known invasive infections. Fluconazole has generally high MIC,
and all isolates were found resistant to ﬂucytosin and echino-
candins [4–6]. Our strain had a high MIC for itraconazole too, al-
though some reports describe favorable outcomes after an itra-
conazole treatment [5,11]. Some reports about other Pseudozyma
species mention also high MICs for ﬂuconazole and itraconazole
and resistance to ﬂucytosine and echinocandins [6,7,11].
The ESCMID and the ECMM recommend a ﬁrst line treatment
of amphotericin B or voriconazole for Pseudozyma infections [2].Indeed, several patients have been successfully treated with am-
photericin B followed by voriconazole per os [4,9].
In our case, the patient had two weeks of liposomal ampho-
tericin B, which seemed, in association with the removal of the
central venous catheter, to have successfully treated the infection.
In conclusion, we need to be aware of the hypothesis of a
Pseudozyma invasive infection when observing unusual yeasts.
More generally, ﬁrst-line treatment with a large spectrum anti-
fungal should be preferred when unusual fungal elements are
isolated from a deep site.Conﬂict of interest
There are none.References
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